Has Shou-Ching Tang received payments from drug or device companies?

Yes. Drug and device makers reported $30,032 in general payments to Shou-Ching Tang across 168 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shou-Ching Tang did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shou-Ching Tang come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shou-Ching Tang

Medical Oncology · Augusta, GANPI 1568421147

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 19.7%. Reporting peaked in 2023 at $9,910 and has fallen 87.5% since, to $1,238 in 2025.

$30,032in general payments, 2019–2025

Across 168 payments — averaging $178.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$6K
Astellas Pharma US Inc$3K
Daiichi Sankyo Inc.$3K
Athenex Pharmaceutical Division, LLC$3K
AstraZeneca$2K
Siemens Medical Solutions USA, Inc.$1K
plus $12K from 50 others

$860,804in research payments, 2019–2025

Across 85 payments — averaging $10,127 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Incyte Corporation$483K
AstraZeneca$187K
Pfizer$54K
Seagen Inc.$51K
GSK$34K
AbbVie$28K
plus $23K from 1 others

What the payments were for

Consulting fees$16,31454%
Speaking & faculty fees$5,46318%
Travel & lodging$7142%
Food & beverage$7,52925%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	13	$5,915
Astellas Pharma US Inc	7	$3,317
Daiichi Sankyo Inc.	5	$2,878
Athenex Pharmaceutical Division, LLC	6	$2,522
AstraZeneca	6	$2,287
Siemens Medical Solutions USA, Inc.	1	$1,463
Tersera Therapeutics LLC	3	$1,425
Genentech USA, Inc.	8	$1,391
BD	2	$1,004
Janssen Scientific Affairs, LLC	9	$868
Lantheus Medical Imaging, Inc.	1	$788
Cepheid	1	$683
Beigene USA, Inc.	2	$667
GE HealthCare	2	$397
Amgen	19	$395
Puma Biotechnology, Inc.	3	$365
Stemline Therapeutics Inc.	2	$276
Johnson & Johnson	9	$261
Foundation Medicine, Inc.	2	$203
Takeda Pharmaceuticals U.S.A., Inc.	6	$203
Exelixis Inc.	3	$193
AbbVie	6	$192
Merck	4	$174
Eisai Inc.	4	$169
Astellas Pharma Global Development	1	$150
Regeneron	1	$144
Immunocore Limited	2	$142
Karyopharm Therapeutics Inc.	2	$138
Astrazeneca UK Limited	1	$135
Medivation Services LLC	1	$130
Tempus AI, Inc	1	$116
Bayer	2	$113
Beone Medicines USA, Inc.	1	$108
Pharmaessentia USA Corporation	1	$100
Macrogenics, Inc.	1	$96
Seagen Inc.	1	$65
F. Hoffmann-la Roche AG	1	$56
Bristol Myers Squibb	3	$55
Genentech, Inc.	2	$54
Gilead	3	$53
Novartis	3	$48
Rigel Pharmaceuticals, Inc.	2	$30
Lilly USA, LLC	2	$29
Adaptive Biotechnologies Corporation	1	$28
Sanofi	1	$25
Blueprint Medicines Corporation	1	$23
Ipsen Biopharmaceuticals, Inc	1	$20
Pharmacyclics LLC, An Abbvie Company	1	$18
GSK	1	$17
Alnylam Pharmaceuticals Inc.	1	$17
Boehringer Ingelheim	1	$16
Servier Pharmaceuticals LLC	1	$16
Clovis Oncology, Inc.	1	$14
EMD Serono, Inc.	1	$14
Helsinn Therapeutics (U.S.), Inc.	1	$13
Secura Bio, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,032 in reported general payments places this provider in the 80th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Other medical oncology in Augusta

Samir KhleifAugusta$337K
Luke StapletonAugusta$412
Nabil SabaAtlanta$225K
Sreekanth ReddyVidalia$116K
Hagop YoussoufianDecatur$78K
Suresh RamalingamAtlanta$75K
Jonathan KaufmanAtlanta$73K
Ragini KudchadkarAtlanta$69K
Nisha JosephAtlanta$50K
Eyal MeiriAtlanta$39K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →